Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 Combination Therapies in Metastatic Colorectal Cancer
NCT07503756Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in metastatic colorectal cancer (mCRC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
JS212
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07503756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503756.